Amino-Terminal Processing of Chemokine ENA-78 Regulates Biological Activity
- 19 December 1998
- journal article
- research article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 38 (2) , 636-642
- https://doi.org/10.1021/bi981294s
Abstract
Epithelial cell-derived neutrophil-activating protein-78 (ENA-78) is a potent stimulator of neutrophils, inducing a variety of biological responses such as chemotaxis, enzyme release, up-regulation of surface receptors, and intracellular calcium mobilization. Proteolysis of ENA-78 with cathepsin G and chymotrypsin yielded a time-dependent increase in elastase-releasing activity, predicting the formation of truncation products with higher potency than native ENA-78. To investigate the biological implications of progressive truncation of ENA-78, the N-terminal variants ENA(5-78), ENA(9-78), and ENA(10-78) were cloned and expressed in E. coli. When tested in the neutrophil elastase release assay, the variants ENA(5-78) and ENA(9-78) had a 2-3-fold higher potency than full-length ENA-78, while ENA(10-78) was 3-fold less potent. In the chemotaxis assay, the variant ENA(5-78) exhibited an 8-fold and ENA(9-78) a 2-fold higher potency than native ENA-78. ENA(10-78), conversely, was 10-fold less potent, but reached a comparable efficacy to ENA-78 at 10(-)7 M concentration. In summary, the rank order in potency with respect to elastase release was ENA(9-78) > ENA(5-78) > ENA-78 > ENA(10-78), while for chemotaxis it was ENA(5-78) > ENA(9-78) > ENA-78 > ENA(10-78). Variant ENA(5-78) had a higher overall potency and efficiency for chemotaxis than interleukin-8 (IL-8), while ENA(9-78) exhibited a higher efficiency at concentrations of 1-100 nM. The fact that neutrophil cathepsin G produces the stable ENA(9-78) variant in vitro strongly suggests a role for this N-terminal proteolysis during inflammatory processes in vivo.Keywords
This publication has 14 references indexed in Scilit:
- Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat. The role of epithelial neutrophil activating protein.Journal of Clinical Investigation, 1995
- Interleukin‐8 processing by neutrophil elastase, cathepsin G and proteinase‐3FEBS Letters, 1994
- Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω‐aminocarboxylic acidsEuropean Journal of Biochemistry, 1994
- Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8.The Journal of Experimental Medicine, 1991
- Generation of interleukin‐8 by plasmin from AVLPR‐interleukin‐8, the human fibroblast‐derived neutrophil chemotactic factorFEBS Letters, 1991
- Comparison of the solution nuclear magnetic resonance and crystal structures of interleukin-8Journal of Molecular Biology, 1991
- Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases.The Journal of Experimental Medicine, 1990
- Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils.The Journal of Experimental Medicine, 1989
- A novel neutrophil-activating factor produced by human mononuclear phagocytes.The Journal of Experimental Medicine, 1988
- Subcellular localization and heterogeneity of neutral proteases in neutrophilic polymorphonuclear leukocytes.The Journal of Experimental Medicine, 1975